S. Hudu, Amira Osman, Esra’a Jebreel Ibrahim Abu-Shoura, A. Jimoh
Hepatitis B therapeutic vaccines hold great promise in the treatment of chronic Hepatitis B virus (HBV) infection. However, like any medical intervention, they also face certain prospects and challenges which forms the aim of this critical review. Therapeutic vaccines offer a targeted approach to manage chronic Hepatitis B infections, aiming to stimulate the immune system to recognise and eliminate infected cells. The potential to halt disease progression holds promise for preventing severe liver diseases associated with chronic Hepatitis B, such as cirrhosis and hepatocellular carcinoma. Therapeutic vaccines, if effective, could contribute to a more equitable distribution of treatment options globally, especially in resource-limited settings. Hepatitis B therapeutic vaccines may play a crucial role in preventing vertical transmission, reducing the global incidence of perinatal HBV infections and improving maternal-child health outcomes. Diverse vaccine platforms and combination strategies, including immunomodulation and checkpoint inhibitors, are advancing, optimising immunogenicity, and eliciting strong immune responses. Tailoring therapeutic vaccines to individual patients based on genetic considerations may enhance efficacy, recognizing the genetic diversity of Hepatitis B. Therapeutic vaccines need to align with global health goals related to infectious disease elimination, contributing to broader efforts to reduce the burden of Hepatitis B worldwide. While Hepatitis B therapeutic vaccines hold significant promise in transforming the management of chronic infections, addressing challenges related to access, viral variability, and long-term monitoring is crucial for their successful integration into global healthcare strategies.
{"title":"A critical review of the prospects and challenges of Hepatitis B therapeutic vaccines","authors":"S. Hudu, Amira Osman, Esra’a Jebreel Ibrahim Abu-Shoura, A. Jimoh","doi":"10.24294/ti.v8.i1.5644","DOIUrl":"https://doi.org/10.24294/ti.v8.i1.5644","url":null,"abstract":"Hepatitis B therapeutic vaccines hold great promise in the treatment of chronic Hepatitis B virus (HBV) infection. However, like any medical intervention, they also face certain prospects and challenges which forms the aim of this critical review. Therapeutic vaccines offer a targeted approach to manage chronic Hepatitis B infections, aiming to stimulate the immune system to recognise and eliminate infected cells. The potential to halt disease progression holds promise for preventing severe liver diseases associated with chronic Hepatitis B, such as cirrhosis and hepatocellular carcinoma. Therapeutic vaccines, if effective, could contribute to a more equitable distribution of treatment options globally, especially in resource-limited settings. Hepatitis B therapeutic vaccines may play a crucial role in preventing vertical transmission, reducing the global incidence of perinatal HBV infections and improving maternal-child health outcomes. Diverse vaccine platforms and combination strategies, including immunomodulation and checkpoint inhibitors, are advancing, optimising immunogenicity, and eliciting strong immune responses. Tailoring therapeutic vaccines to individual patients based on genetic considerations may enhance efficacy, recognizing the genetic diversity of Hepatitis B. Therapeutic vaccines need to align with global health goals related to infectious disease elimination, contributing to broader efforts to reduce the burden of Hepatitis B worldwide. While Hepatitis B therapeutic vaccines hold significant promise in transforming the management of chronic infections, addressing challenges related to access, viral variability, and long-term monitoring is crucial for their successful integration into global healthcare strategies.","PeriodicalId":504215,"journal":{"name":"Trends in Immunotherapy","volume":"142 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141375928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
W. Y. M. Al-dulaimy, Khalid Shaalan Sahab, Ebtehal Sabri Mohammed, Mohammed Kadhom
The objective of this research was to determine the change in hepcidin levels and other biochemical markers, including total iron binding capacity (TIBC), serum iron, testosterone, and specific vitamins in the blood of individuals with β-Thalassemia. Here, 140 participants were involved in the study, of whom 110 were affected by β-thalassemia and 30 were healthy. The samples were obtained from Baqubah Teaching Hospital, the blood bank and blood donation center. The study was carried out from May 2022 to August 2022, and the patients were housed in Diyala Provence, Baquba City and its suburbs. The participants in this investigation were split into three groups: A: 55 male patients with β-thalassemia; B: 55 female patients with β-thalassemia; and C: 30 healthy individuals that were set as a control group. The findings of the study showed that the levels of HbA1 in males and females were 93.44 ± 0.71 and 93.53 ± 0.91, respectively, while the levels of HbA2 in males and females were 4.99 ± 0.59 and 5.29 ± 0.72, respectively. In contrast, the control group had HbA1 levels of 97.33 ± 0.40 in males and 97.66 ± 0.46 in females, but HbA2 levels were 2.32 ± 0.33 in males and 2.24 ± 0.24 in females. The study revealed remarkable differences (P < 0.05) between these variables. Hematological measures, such as hemoglobin concentration and percentages of mean corpuscular volume (MCV), packed cell volume (PCV), and mean corpuscular hemoglobin (MCH) were substantially reduced (P < 0.05) in β-thalassemia patients when compared to the controls. Serum iron and TIBC were significantly increased (P < 0.05), while Hepcidin levels were markedly decreased (P < 0.05) in the serum of β-thalassemia patients compared to controls. Therefore, as a conclusion the reduction of hepcidin levels and increase in iron levels are correlated with β-thalassemia and can be used as a biomarkers in monitoring β-thalassemia disease.
{"title":"Role of blood hepcidin alteration as a biomarker in β-thalassemia patients’ diagnosis","authors":"W. Y. M. Al-dulaimy, Khalid Shaalan Sahab, Ebtehal Sabri Mohammed, Mohammed Kadhom","doi":"10.24294/ti.v8.i1.4397","DOIUrl":"https://doi.org/10.24294/ti.v8.i1.4397","url":null,"abstract":"The objective of this research was to determine the change in hepcidin levels and other biochemical markers, including total iron binding capacity (TIBC), serum iron, testosterone, and specific vitamins in the blood of individuals with β-Thalassemia. Here, 140 participants were involved in the study, of whom 110 were affected by β-thalassemia and 30 were healthy. The samples were obtained from Baqubah Teaching Hospital, the blood bank and blood donation center. The study was carried out from May 2022 to August 2022, and the patients were housed in Diyala Provence, Baquba City and its suburbs. The participants in this investigation were split into three groups: A: 55 male patients with β-thalassemia; B: 55 female patients with β-thalassemia; and C: 30 healthy individuals that were set as a control group. The findings of the study showed that the levels of HbA1 in males and females were 93.44 ± 0.71 and 93.53 ± 0.91, respectively, while the levels of HbA2 in males and females were 4.99 ± 0.59 and 5.29 ± 0.72, respectively. In contrast, the control group had HbA1 levels of 97.33 ± 0.40 in males and 97.66 ± 0.46 in females, but HbA2 levels were 2.32 ± 0.33 in males and 2.24 ± 0.24 in females. The study revealed remarkable differences (P < 0.05) between these variables. Hematological measures, such as hemoglobin concentration and percentages of mean corpuscular volume (MCV), packed cell volume (PCV), and mean corpuscular hemoglobin (MCH) were substantially reduced (P < 0.05) in β-thalassemia patients when compared to the controls. Serum iron and TIBC were significantly increased (P < 0.05), while Hepcidin levels were markedly decreased (P < 0.05) in the serum of β-thalassemia patients compared to controls. Therefore, as a conclusion the reduction of hepcidin levels and increase in iron levels are correlated with β-thalassemia and can be used as a biomarkers in monitoring β-thalassemia disease.","PeriodicalId":504215,"journal":{"name":"Trends in Immunotherapy","volume":"83 20","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140675269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mohamed Bilal Moosa, Devayani Josh, Reshma Bobby, Besty Biju, J. Sebastian, Sheba Baby John, M. Ravi
Objectives: This study aimed to assess the hesitancy towards vaccination and to identify the factors and predictor variables within the study population. Methodology: This was a cross-sectional study conducted via a web-based platform where a validated questionnaire was circulated among the public to understand their hesitancy towards vaccination. WHO SAGE Working Group Questionnaire was used to collect the data. The predictors for hesitancy were determined by using bivariate logistic regression analysis and the prevalence of vaccine hesitancy was identified. Results: A total of 353 subjects enrolled in the study during the 6 months of the study. Among them, 133 (37.67%) subjects showed vaccine hesitancy. On performing the bi-variate analysis, it was found that among the subsets studies those who were more hesitant to receive vaccines were females (OR: 1.476); individuals who are widowed/separated/divorced (OR: 3.109), age 40–49 yrs (OR: 3.710); from a rural (OR: 1.277) and not graduated (OR: 1.077). These subsets were predictors identified for vaccine hesitancy. Among the vaccines, maximum hesitancy was observed for the chicken pox vaccine [47 (13.31%)], followed by TCV [25 (7.08%)] and Rota [24 (6.79%), whereas the minimum hesitancy was observed for BCG [2 (0.56%)], OPV [4 (1.13%)] and IPV [8 (2.26%)]. Reasons provided for the hesitancy observed were mainly (i) Did not think it was needed [163 (46.17%)], (ii) Did not think the vaccine was safe [41 (11.61%)] and (iii) Did not know where to get vaccinated [24 (6.79%)]. Conclusion: The study observed less vaccine hesitancy among vaccines included in the EPI program. A major contributing factor for VH among the study population was their wrong perception about vaccines as that is not needed and not safe. Hence, there is a real need for education to the population to improve vaccine confidence among the general population.
{"title":"Factors influencing the hesitancy and refusal of vaccines in India: A study-using tool developed by WHO SAGE Working Group","authors":"Mohamed Bilal Moosa, Devayani Josh, Reshma Bobby, Besty Biju, J. Sebastian, Sheba Baby John, M. Ravi","doi":"10.24294/ti.v8.i1.3310","DOIUrl":"https://doi.org/10.24294/ti.v8.i1.3310","url":null,"abstract":"Objectives: This study aimed to assess the hesitancy towards vaccination and to identify the factors and predictor variables within the study population. Methodology: This was a cross-sectional study conducted via a web-based platform where a validated questionnaire was circulated among the public to understand their hesitancy towards vaccination. WHO SAGE Working Group Questionnaire was used to collect the data. The predictors for hesitancy were determined by using bivariate logistic regression analysis and the prevalence of vaccine hesitancy was identified. Results: A total of 353 subjects enrolled in the study during the 6 months of the study. Among them, 133 (37.67%) subjects showed vaccine hesitancy. On performing the bi-variate analysis, it was found that among the subsets studies those who were more hesitant to receive vaccines were females (OR: 1.476); individuals who are widowed/separated/divorced (OR: 3.109), age 40–49 yrs (OR: 3.710); from a rural (OR: 1.277) and not graduated (OR: 1.077). These subsets were predictors identified for vaccine hesitancy. Among the vaccines, maximum hesitancy was observed for the chicken pox vaccine [47 (13.31%)], followed by TCV [25 (7.08%)] and Rota [24 (6.79%), whereas the minimum hesitancy was observed for BCG [2 (0.56%)], OPV [4 (1.13%)] and IPV [8 (2.26%)]. Reasons provided for the hesitancy observed were mainly (i) Did not think it was needed [163 (46.17%)], (ii) Did not think the vaccine was safe [41 (11.61%)] and (iii) Did not know where to get vaccinated [24 (6.79%)]. Conclusion: The study observed less vaccine hesitancy among vaccines included in the EPI program. A major contributing factor for VH among the study population was their wrong perception about vaccines as that is not needed and not safe. Hence, there is a real need for education to the population to improve vaccine confidence among the general population.","PeriodicalId":504215,"journal":{"name":"Trends in Immunotherapy","volume":"14 17","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140712943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：